Sandbox:farnaz: Difference between revisions
Jump to navigation
Jump to search
Usama Talib (talk | contribs) |
Usama Talib (talk | contribs) No edit summary |
||
| Line 26: | Line 26: | ||
{{familytree/end}} | {{familytree/end}} | ||
=== Type 2 | === Type 2 === | ||
The primary therapy for MS may include:<ref name="pmid25095894">{{cite journal| author=Kamm CP, Uitdehaag BM, Polman CH| title=Multiple sclerosis: current knowledge and future outlook. | journal=Eur Neurol | year= 2014 | volume= 72 | issue= 3-4 | pages= 132-41 | pmid=25095894 | doi=10.1159/000360528 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25095894 }} </ref><ref name="pmid29270309">{{cite journal| author=Schwartz K, Wymbs NF, Huang H, Mealy MA, Pardo CA, Zackowski K et al.| title=Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis. | journal=Mult Scler J Exp Transl Clin | year= 2017 | volume= 3 | issue= 4 | pages= 2055217317740145 | pmid=29270309 | doi=10.1177/2055217317740145 | pmc=5731631 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29270309 }} </ref> | The primary therapy for MS may include:<ref name="pmid25095894">{{cite journal| author=Kamm CP, Uitdehaag BM, Polman CH| title=Multiple sclerosis: current knowledge and future outlook. | journal=Eur Neurol | year= 2014 | volume= 72 | issue= 3-4 | pages= 132-41 | pmid=25095894 | doi=10.1159/000360528 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25095894 }} </ref><ref name="pmid29270309">{{cite journal| author=Schwartz K, Wymbs NF, Huang H, Mealy MA, Pardo CA, Zackowski K et al.| title=Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis. | journal=Mult Scler J Exp Transl Clin | year= 2017 | volume= 3 | issue= 4 | pages= 2055217317740145 | pmid=29270309 | doi=10.1177/2055217317740145 | pmc=5731631 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29270309 }} </ref> | ||
*B-interferon | *B-interferon | ||
Revision as of 21:30, 9 February 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farnaz Khalighinejad, MD [2]
Overview
This is my sandbox.
Image reference
Source: Wikimedia commons
Type 1:
| Pulmonary edema | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cardiogenic | Non-cardiogenic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LV failure | Dysrthmia | LV hypertrophy and cardiomyopathy | Volume Overload | MI | LV outflow obstruction | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| E02 | E03 | E04 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| F01 | F02 | F03 | F04 | F05 | F06 | F07 | F08 | F09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| G01 | G02 | G03 | G04 | G05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Type 2
The primary therapy for MS may include:[1][2]
- B-interferon
- Teleflunomide
96 patients (174 eyes, 70% females) were included with a mean age at presentation of 30 years
| Cause | Symptom | Diagnosis | Treatment |
|---|---|---|---|
| 1 | |||
| 2 | |||
| 3 |
References
- ↑ Kamm CP, Uitdehaag BM, Polman CH (2014). "Multiple sclerosis: current knowledge and future outlook". Eur Neurol. 72 (3–4): 132–41. doi:10.1159/000360528. PMID 25095894.
- ↑ Schwartz K, Wymbs NF, Huang H, Mealy MA, Pardo CA, Zackowski K; et al. (2017). "Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis". Mult Scler J Exp Transl Clin. 3 (4): 2055217317740145. doi:10.1177/2055217317740145. PMC 5731631. PMID 29270309.